As of 2025-12-23, the Intrinsic Value of Halozyme Therapeutics Inc (HALO) is 89.79 USD. This HALO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 68.16 USD, the upside of Halozyme Therapeutics Inc is 31.70%.
The range of the Intrinsic Value is 66.96 - 135.23 USD
Based on its market price of 68.16 USD and our intrinsic valuation, Halozyme Therapeutics Inc (HALO) is undervalued by 31.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 66.96 - 135.23 | 89.79 | 31.7% |
| DCF (Growth 10y) | 103.21 - 198.82 | 135.39 | 98.6% |
| DCF (EBITDA 5y) | 116.60 - 145.87 | 124.11 | 82.1% |
| DCF (EBITDA 10y) | 148.64 - 197.91 | 164.52 | 141.4% |
| Fair Value | 126.59 - 126.59 | 126.59 | 85.73% |
| P/E | 78.17 - 119.28 | 87.79 | 28.8% |
| EV/EBITDA | 106.39 - 265.59 | 165.32 | 142.5% |
| EPV | 26.66 - 37.81 | 32.23 | -52.7% |
| DDM - Stable | 36.68 - 90.30 | 63.49 | -6.8% |
| DDM - Multi | 60.14 - 115.98 | 79.30 | 16.3% |
| Market Cap (mil) | 8,015.62 |
| Beta | -0.06 |
| Outstanding shares (mil) | 117.60 |
| Enterprise Value (mil) | 9,106.71 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.35% |
| Cost of Debt | 4.25% |
| WACC | 8.41% |